Abstract:Abstract Oridonin, a diterpenoid derived from the herbal Rabdosia rubescens, has been reported to have antitumor effects on various types of cancer cells. However, its relatively low aqueous solubility and bioavailability have limited its development into clinical applications. Herein, we chemically modified oridonin and generated a series of novel analogues. We then employed MTT assay to detect their effects on cell growth and a number of new and potent molecules have been identified. Among them, compounds CYD-6-86 and CYD-6-92 significantly inhibited the proliferation of human breast cancer MDA-MB-231 and MCF-7 cells. Furthermore, both compounds induced enhanced apoptosis in a dose- and time-dependent fashion when compared with oridonin. Cell cycle analysis indicated that both CYD-6-86 and CYD-6-92 induced S phase arrest in MDA-MB-231 cells and G0/G1 phase arrest in MCF-7 cells, while oridonin induced G2/M phase arrest in MDA-MB-231 and MCF-7 cells. Consistent with oridonin, Western blot analysis showed that CYD-6-86 and CYD-6-92 inhibited the expression of NF-κB and Bcl-2, and increased expression of Bax and cleaved PARP. Intriguingly, compounds CYD-6-86 and CYD-6-92 have demonstrated to suppress the growth of adriamycin-resistant MCF-7 clone, while at the same dosage oridonin displayed no effect on these cells. Our findings suggest that these new analogues may be superior to the natural product oridonin to overcome the chemo-resistance, and have great potential to be developed as novel therapeutics for the treatment of breast cancer. Citation Format: Yusong Zhang, Chunyong Ding, Zhengduo Yang, Haijun Chen, Lili Chu, Jia Zhou, Qiang Shen. Discovery of potent oridonin derivatives for the treatment of breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5573. doi:10.1158/1538-7445.AM2013-5573

In vitro identification of oridonin hybrids as potential anti-TNBC agents inducing cell cycle arrest and apoptosis by regulation of p21, γH2AX and cleaved PARP

Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer

Oridonin Inhibits Bxpc-3 Cell Growth Through Cell Apoptosis

A New Oridonin Analog Suppresses Triple-Negative Breast Cancer Cells and Tumor Growth Via the Induction of Death Receptor 5

Identification of New Potent Anticancer Derivatives Through Simplifying the Core Structure and Modification on Their 14- Hydroxyl Group from Oridonin.

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest Through the Mitochondrial Pathway

Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer

Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 14-Substituted Oridonin Analogs: A Novel and Potent Cell Cycle Arrest and Apoptosis Inducer Through the P53-Mdm2 Pathway.

Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer

Novel Hybrids of Natural Oridonin-Bearing Nitrogen Mustards As Potential Anticancer Drug Candidates.

Discovery of acetophenone/piperazin-2-one hybrids as selective anti-TNBC cancer agents by causing DNA damage

Design and synthesis of novel oridonin analogues as potent anticancer agents.

Design, Synthesis, and Biological Evaluation of Novel 4,4′-Bipyridine Derivatives Acting As CDK9-Cyclin T1 Protein-Protein Interaction Inhibitors Against Triple-Negative Breast Cancer

Abstract 5573: Discovery of Potent Oridonin Derivatives for the Treatment of Breast Cancer.

Discovery of Novel PI3K/CDK2 Dual Inhibitor Based on 7-Azaindole Derivatives As a Promising Strategy for Triple-Negative Breast Cancer Therapy

Synthesis and Structure-Activity Relationship Studies of Parthenolide Derivatives As Potential Anti-Triple Negative Breast Cancer Agents

Novel Nitrogen-Enriched Oridonin Analogues with Thiazole-Fused A-Ring: Protecting Group-Free Synthesis, Enhanced Anticancer Profile, and Improved Aqueous Solubility

Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA

Discovery and identification of a novel PI3K inhibitor with enhanced CDK2 inhibition for the treatment of triple negative breast cancer

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer